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GENE EXPRESSION PROFILES OF 4-HYDROXY-N-
DESMETHYL-TAMOXIFEN (ENDOXIFEN)- AND 4-HYDROXY-
TAMOXIFEN (4OHTAM)-TREATED HUMAN BREAST CAN-
CER CELLS DETERMINED BY CDNA MICROARRAY
ANALYSIS. Y. Lim, MD, PhD, L. Li, PhD, Z. Desta, PhD, J. M.
Rae, PhD, D. A. Flockhart, MD, PhD, T. C. Skaar, PhD, Indiana
University, University of Michigan, Indianapolis, IN.
Recently, we have shown that endoxifen and 4OHTAM are equi-
potent inhibitors of estrogen action, with respect to estrogen receptor
(ER) binding, proliferation, and inhibition of pS2 and PR gene
expression. Since estrogens and anti-estrogens have effects on the
expression of many additional genes, we tested the effects of endox-
ifen and 4OHTAM on genome-wide profiling in ER-positive MCF-7
cell lines by cDNA microarray analysis using the Affymetrix HG-
U133A GeneChip. Cells were treated for 24 hrs with vehicle, 17-
estradiol (E2) 1010M, 4OHTAM 107M, endoxifen 107M,
E24OHTAM, E2endoxifen, and E24OHTAMendoxifen. E2
treatment resulted in up- or down-regulation of 
213 genes which
showed greater than 2-fold changes from the vehicle-treated group.
4OHTAM and endoxifen changed the expression of 58 and 52 genes
respectively when added to the E2 treatment. Of these genes, 49
(84.5%) and 46 (88.5%) were estrogen-regulated genes. 4OHTAM
and endoxifen had overlapping effects on 32 genes, but also brought
about distinct patterns of gene regulation (26 vs. 20 genes were
changed by only 4OHTAM or endoxifen, resp.). Among the 32 genes
coregulated by both 4OHTAM and endoxifen, there was a significant
correlation between the fold-effects brought about by these two drugs
(R20.964, P0.01). These data indicate that the majority of genes
influenced by active tamoxifen metabolites are estrogen-sensitive
genes, but that some effects of tamoxifen may be estrogen-
independent.
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THE EFFECT OF HOMOCYSTEINE ON THE PRODUCTION
OF INFLAMMATORY CYTOKINES. Y. Asanuma, MD, PhD, A.
Oeser, BSc, E. Stanley, A. Shintani, PhD, C. M. Stein, MD, St.
Marianna University School of Medicine, Vanderbilt University
School of Medicine, Kawasaki, Japan.
Elevated C-reactive protein (CRP), homocysteine and inflamma-
tory cytokines such as interleukin-6 (IL-6) are associated with in-
creased cardiovascular risk. CRP has direct inflammatory actions
stimulating the production of IL-6 and monocyte chemoattactant
protein-1, (MCP-1) in whole blood. Homocysteine increases the
production of MCP-1 and IL-8 in endothelial cells in vitro, but
whether it has direct inflammatory actions in an environment more
representative of in vivo biology, is not known. Thus, we examined
the hypothesis that homocysteine would stimulate the production of
IL-6 and MCP-1 in whole blood. Blood was drawn from 15 healthy
subjects and incubated with saline, 1	g/ml lipopolysaccaride (LPS),
50 (n8) and 100 	M/L (n6) DL-homocysteine or 5 	g/ml human
recombinant CRP for 24 hours. Both CRP and LPS significantly
increased the production of IL-6 and MCP-1 more than 4-fold
(P0.001) but homocysteine did not. Homocysteine had little effect
on IL-6 (fold change at 24 hours 1.40.4 (SEM) vs. baseline,
P0.14) or MCP-1 (0.94.5, P0.08) production. Thus, concentra-
tions of homocysteine that had inflammatory effects in vitro, and are
in the range that occur in patients with hyperhomocystinemia had no
effect on IL-6 or MCP-1 production in whole blood. A possible
explanation is that the whole blood environment provides antioxidant
defenses not present in cell culture and may thus attenuate the
inflammatory effects of homocysteine, thought to be mediated by free
radicals.
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COX-2 INHIBITORS AND CARBONIC ANHYDRASE ACTIV-
ITY. J. F. Knudsen, MD, PhD, U. Carlsson, PhD, P. Hammarstro¨m,
PhD, G. H. Sokol, MD, L. R. Cantilena, Jr., MD, PhD, Uniformed
Services University of the Health Sciences, Bethesda, MD.
Purpose: To compare the carbonic anhydrase inhibition (CAI)
profile of selective and non-selective COX-2 inhibitors with the
prototypic CAI acetazolamide (ACZ). Methods: The CO2 hydration
activity of human carbonic anhydrase II (hCAII ) was determined by
a colorimetric method. The enzyme concentration was 5nM. Stock
solutions of the inhibitors were dissolved in either ethanol or DMSO.
The fraction of inhibitory activity was calculated by comparing CO2
hydration activity of the enzyme in the absence and presence of the
test compounds (tested blind to the study hypothesis). Duplicate
determinations were performed. Commercially available compounds
purchased at the pharmacy and excipient free compounds were used.
Results: The IC50 (nM) values (from the most potent CAI to least)
were: ACZ, 7.5; celecoxib, 410; valdecoxib, 24800; rofecoxib 
3X10 5 and diclofenac  3X10 5. The structural basis underlying the
differences in potency is in all likelihood the pharmacophore
SO2NH2, the common molecular moiety of acetazolamide, celecoxib
and valdecoxib. The sulfonamide motif is absent from rofecoxib and
diclofenac. Discussion: We have demonstrated an unusual inhibition
binding profile for the COX-2 inhibitor celecoxib against hCAII, an
isozyme with numerous physiological roles. The nanomolar CAI is
linked to the pharmacophore SO2 NH2. We suggest that celecoxib
may mediate some of its actions, e.g. anti-cancer effects, HCO3-
modulation, by the COX-2 independent mechanism of CAI.
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THE PUTATIVE TUMOR SUPPRESSOR CDX2 IS OVER-
EXPRESSED IN HUMAN COLONIC ADENOCARCINOMAS. M.
Witek, J. Park, MD, PhD, R. Walters, K. Neilsen, S. Schulz, PhD, J.
Palazzo, MD, S.A. Waldman, MD, PhD, Thomas Jefferson Univer-
sity, Philadelphia, PA.
Cdx2, an intestine-specific transcription factor, regulates genes
that define the differentiated phenotype of enterocytes. Loss of Cdx2
has been suggested to underlie the progression of carcinomas in the
colon and rectum. Here, expression of Cdx2 determined by quanti-
tative reverse transcriptase-polymerase chain reaction (RNA) and
immunohistochemistry (protein), in primary and metastatic colorectal
tumors was compared to that in normal segments of the colonic
epithelium. Surprisingly, Cdx2 was over-expressed by tumors, com-
pared to normal mucosa in colon. Furthermore, Cdx2 was detected in
lymph nodes containing metastatic cancer cells but not in those free
of tumor. Thus, loss of Cdx2 expression does not contribute to
mechanisms underlying neoplastic transformation of the colonic ep-
ithelium. Of clinical significance, Cdx2 is a molecular marker with
utility for managing patients with colorectal malignancies.
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